Skip to main content
Premium Trial:

Request an Annual Quote

Pyrosequencing Hopes to Change Name to Biotage

NEW YORK, Oct. 23 (GenomeWeb News) - Pyrosequencing may soon change its name to Biotage, the small-molecule purification and separation-systems company it acquired last week, Pyrosequencing said today.


The name change, which Pyrosequencing said would not affect the company's distinctive logo, must be approved by shareholders during an upcoming meeting. The company said it will call for a shareholders' meeting "shortly."

Pyrosequencing will also get a new organizational structure, which will comprise two business areas: Biosystems and Discovery Chemistry. Hans Johansson, president of Pyrosequencing, will be the head of Biosystems, and David Patteson, president of Biotage, will run Discovery Chemistry.

Jeff Bork, who had been chairman and CEO of Pyrosequencing, will become president and CEO of the new company Biotage. Ove Mattsson, previously chairman of the board of Personal Chemistry, will be chairman of the new Biotage.

As GenomeWeb News reporter, Pyrosequencing said on Oct. 14 that it had entered into an agreement with Dyax to acquire Biotage, a wholly owned subsidiary, for approximately $35 million in cash.

Pyrosequencing, which expanded its product line to include medicinal chemistry following its recent acquisition of Personal Chemistry, said the Biotage acquisition would enhance its chemistry portfolio.

Pyrosequencing said it plans to take over the mortgage on Biotage's newly built premises in Virginia, which will reduce the purchase price to approximately $30 million.

Biotage reported net sales of $23.2 million in 2002. The company has 126 employees.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.